‘Closing in on cancer’ in ultra modern and super flexible laboratories
Merus commissioned Stone22 to supervise the selection of the developer of the ‘Accelerator’ and to monitor and guide the development and realization of this building on the Utrecht Science Park campus.
In addition to monitoring and guiding the development of the Accelerator of 20,000 m2 GFA, Stone22 developed and realized Merus’ complete-use specifications, delivering a facility ready to-use, including the offices and laboratory equipment.
Merus conducts research into the development of clinically advanced, targeted treatments to address the needs of patients with various types of cancer. Using patented technology platforms, Merus develops innovative multi-specific antibody therapies, also called Multiclonics.
The laboratory design is distinguished by a highly flexible setup, which allows for quick and easy adjustments to the lab layout, an important feature in this dynamic research environment.
